Janux Therapeutics gains amid renewed takevover speculation
Source: SeekingAlpha
2025-10-28 10:11:44 ET
More on Janux Therapeutics
- Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
- Janux is a new Buy at Truist ahead of catalyst rich H2
- Piper Sandler initiates coverage of oncology companies
- Seeking Alpha’s Quant Rating on Janux Therapeutics
- Historical earnings data for Janux Therapeutics
Read the full article on Seeking Alpha
For further details see:
Janux Therapeutics gains amid renewed takevover speculation
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
0.82% G/L:
$14.165 Last:
397,240 Volume:
$14.12 Open:
JANX Latest News
February 26, 2026 04:01:00 pm
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 17, 2026 07:00:00 am
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
January 26, 2026 07:00:00 am
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
